AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12679832 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairs Climbing (SC)
Number of subjects: 32
Study 12679832 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES)
Number of subjects: 32
Study 12679832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Stairs Climbing and Electrostimulation (SC+ES)
Number of subjects: 32
Study 12679832 — intervention group
Group type: COMPARATOR
Intervention: Control (SC and ES)
Number of subjects: 32
Study 10920696 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Head Injury Severity Scale; routine early computerized tomography (CT) scan for mild injuries; mandatory CT scan and admission for moderate injuries.
Number of subjects: 0
Study 8803994 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable potassium concentration dialysis
Number of subjects: 36
Study 8803994 — intervention group
Group type: COMPARATOR
Intervention: Constant potassium concentration dialysis
Number of subjects: 36
Study 1517839 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐chimeric B72.3 (IgG‐4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions
Number of subjects: 12
Study 1517839 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐chimeric B72.3 (IgG‐4) at total doses of 36 mCi/m2
Number of subjects: 12
Study 1517839 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐chimeric B72.3 (IgG‐4)
Number of subjects: 12
Study 1517839 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of therapy with 131I‐chimeric B72.3 (IgG‐4)
Number of subjects: 12
Study 1517839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose fractionation of 131I‐chimeric B72.3 (IgG‐4)
Number of subjects: 12
Study 6468471 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR 2647 combination (2 sachets b.i.d. on the day of operation, 1 sachet b.i.d. for the following two days)
Number of subjects: 53
Study 6468471 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (2 tablets q.i.d. on the day of operation, 1 tablet q.i.d. for the following two days)
Number of subjects: 53
Study 30417227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 0.015 mg/ml epinephrine (Group A)
Number of subjects: 0
Study 30417227 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 0.015 mg/ml epinephrine (Group B)
Number of subjects: 0
Study 30417227 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 0.012 mg/ml epinephrine (Group C)
Number of subjects: 0
Study 29241091 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago exercise program (6 months)
Number of subjects: 77
Study 29241091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 77
Study 25676674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole OD 30 mg from a nasogastric tube for 14 days
Number of subjects: 120
Study 25676674 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group)
Number of subjects: 120
Study 25035620 — intervention group
Group type: EXPERIMENTAL
Intervention: Laghu Sankhaprakshalana (LSP)
Number of subjects: 40
Study 25035620 — intervention group
Group type: COMPARATOR
Intervention: Back pain specific asanas (BST)
Number of subjects: 40
Study 22257450 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic training program, 5 days/week, at low/moderate intensity
Number of subjects: 100
Study 22257450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 100
Study 20040336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (BF) administration
Number of subjects: 0
Study 18346626 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy using magnetic pellets (experimental group)
Number of subjects: 60
Study 18346626 — intervention group
Group type: COMPARATOR
Intervention: Semen vaccariae (control group)
Number of subjects: 60
Study 15738932 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 1249
Study 15738932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1249
Study 12627305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWIG, n=9)
Number of subjects: 28
Study 12627305 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-cold-water immersion (DCWIG, n=9)
Number of subjects: 28
Study 12627305 — intervention group
Group type: COMPARATOR
Intervention: Control group (COTG, n=10)
Number of subjects: 28
Study 11052843 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective stent placement (7‐cell NIR stent)
Number of subjects: 120
Study 11052843 — intervention group
Group type: COMPARATOR
Intervention: Optimal balloon angioplasty
Number of subjects: 120
Study 8826310 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated medication distribution systems
Number of subjects: 0
Study 8826310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis
Number of subjects: 0
Study 1425647 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min at 60% VO2max
Number of subjects: 8
Study 1425647 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min at 60% VO2max
Number of subjects: 8
Study 1425647 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min at 70% VO2max
Number of subjects: 8
Study 1425647 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min at 70% VO2max
Number of subjects: 8
Study 1425647 — intervention group
Group type: EXPERIMENTAL
Intervention: All sessions
Number of subjects: 8
Study 3931802 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercises including breathing exercises, suryanamaskar, yogasana, pranayama, dhyana, and a devotional session practiced for 65 minutes daily.
Number of subjects: 53
Study 3931802 — intervention group
Group type: COMPARATOR
Intervention: Usual drugs (control group).
Number of subjects: 53
Study 29300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Salk polio vaccine
Number of subjects: 0
Study 29300977 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27609809 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03A or AS03B)
Number of subjects: 420
Study 27609809 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 420
Study 27609809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 27609809 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines
Number of subjects: 420
Study 24768811 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n=9), 3 days/week for 8 weeks at 60%-80% of baseline peak VO2
Number of subjects: 19
Study 24768811 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n=9)
Number of subjects: 19
Study 24768811 — intervention group
Group type: COMPARATOR
Intervention: Usual care (controls, n=10)
Number of subjects: 19
Study 22234380 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (10-min moderate-intensity stationary cycling)
Number of subjects: 20
Study 22234380 — intervention group
Group type: COMPARATOR
Intervention: Passive control (seating for the same duration)
Number of subjects: 20
Study 21291034 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/day 17beta‐estradiol (E2) orally with progesterone vaginal gel
Number of subjects: 60
Study 21291034 — intervention group
Group type: COMPARATOR
Intervention: Progesterone vaginal gel without 6 mg/day 17beta‐estradiol (E2)
Number of subjects: 60
Study 18344178 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant tablets
Number of subjects: 0
Study 18344178 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 15779884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure to target nameless objects
Number of subjects: 0
Study 15779884 — intervention group
Group type: COMPARATOR
Intervention: No pre-exposure to objects
Number of subjects: 0
Study 15779884 — intervention group
Group type: COMPARATOR
Intervention: Pre-exposure to non-target members of nameless object categories
Number of subjects: 0
Study 15779884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure to a nameless object
Number of subjects: 0
Study 15779884 — intervention group
Group type: COMPARATOR
Intervention: Familiar object or unfamiliar object not pre-exposed
Number of subjects: 0
Study 12053635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 100 mg/d)
Number of subjects: 87
Study 12053635 — intervention group
Group type: COMPARATOR
Intervention: St John's wort (900 to 1800 mg/d)
Number of subjects: 87
Study 12053635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 87
Study 12053635 — intervention group
Group type: COMPARATOR
Intervention: St John's wort
Number of subjects: 87
Study 11895822 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Informed Choice leaflets in intervention units
Number of subjects: 6432
Study 11895822 — intervention group
Group type: COMPARATOR
Intervention: Usual care in control units
Number of subjects: 6432
Study 9541155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 385
Study 9541155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 7542268 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR assay
Number of subjects: 94
Study 2364508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (1,4‐dihydro‐2,6‐dimethyl‐4‐[m‐nitrophenyl]‐3,5‐pyridine‐dicarboxylic acid ethyl methylester)
Number of subjects: 40
Study 2364508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 40
Study 534318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7-10 days
Number of subjects: 26
Study 534318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet for 9 weeks
Number of subjects: 26
Study 534318 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 26
Study 6354607 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg proglumetacin twice daily
Number of subjects: 40
Study 6354607 — intervention group
Group type: COMPARATOR
Intervention: 250 mg naproxen twice daily
Number of subjects: 40
Study 6354607 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumetacin
Number of subjects: 40
Study 6354607 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 40
Study 6354607 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 30156201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage closure (Push back palatoplasty)
Number of subjects: 55
Study 30156201 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without CLP)
Number of subjects: 55
Study 26040978 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin (OT)
Number of subjects: 304
Study 26040978 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU intranasal vasopressin (AVP)
Number of subjects: 304
Study 26040978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 25041312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitzpatrick Skin Type Scale - Sun Exposure subscale
Number of subjects: 244
Study 25041312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitzpatrick Skin Type Scale - Genetic Disposition subscale
Number of subjects: 244
Study 25041312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitzpatrick Skin Type Scale - Tanning Habits subscale
Number of subjects: 244
Study 22297104 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PRFE device
Number of subjects: 70
Study 22297104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study 20593944 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based educational messages on cervical cancer and its prevention (intervention group)
Number of subjects: 350
Study 20593944 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 350
Study 17306565 — intervention group
Group type: EXPERIMENTAL
Intervention: High predictability of action effect
Number of subjects: 0
Study 17306565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low predictability of action effect
Number of subjects: 0
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant products (commercially available fortified infant cereals/ready-to-eat canned baby foods/formula milk powder)
Number of subjects: 475
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant cereals
Number of subjects: 475
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat canned baby foods
Number of subjects: 475
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary diet
Number of subjects: 475
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal products
Number of subjects: 475
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 475
Study 15975182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-A-rich fruit and vegetables
Number of subjects: 475
Study 14728544 — intervention group
Group type: EXPERIMENTAL
Intervention: Back safety training intervention
Number of subjects: 0
Study 14728544 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient transfer training intervention
Number of subjects: 0
Study 14728544 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10643685 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise (30% of VO2max for 60 min)
Number of subjects: 32
Study 10643685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (60% of VO2max for 30 min)
Number of subjects: 32
Study 8656259 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 2 micrograms/mL
Number of subjects: 49
Study 8656259 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 3 micrograms/mL
Number of subjects: 49
Study 1497928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mediastinoscopy
Number of subjects: 95
Study 1497928 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior mediastinotomy
Number of subjects: 95
Study 1497928 — intervention group
Group type: COMPARATOR
Intervention: Both procedures (anterior mediastinotomy and cervical mediastinoscopy)
Number of subjects: 95
Study 6694336 — intervention group
Group type: EXPERIMENTAL
Intervention: Track-and-field athletics training for 9 months
Number of subjects: 21
Study 6694336 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 21
Study 30715758 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin membrane (test group)
Number of subjects: 27
Study 30715758 — intervention group
Group type: COMPARATOR
Intervention: Inorganic bovine bone substitute and a resorbable collagen barrier membrane (control group)
Number of subjects: 27
Study 30715758 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisor and canine region (subgroup)
Number of subjects: 27
Study 30715758 — intervention group
Group type: EXPERIMENTAL
Intervention: Premolar region (subgroup)
Number of subjects: 27
Study 30620868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1450 ppm fluoride as sodium fluoride in a silica base, Test 1
Number of subjects: 180
Study 30620868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1000 ppm fluoride as sodium fluoride in a silica base, Test 2
Number of subjects: 180
Study 30620868 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride as sodium fluoride in a silica base, Control
Number of subjects: 180
Study 27264058 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU cholecalciferol daily
Number of subjects: 474
Study 27264058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 23931093 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 156
Study 23931093 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 156
Study 21975293 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH (acute normovolemic hemodilution)
Number of subjects: 93
Study 21975293 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 93
Study 20152212 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 20
Study 20152212 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 20
Study 18831983 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger subjects; performance improved when elements were aligned along the contour path.
Number of subjects: 0
Study 18831983 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects; performance not affected by the orientation of local elements.
Number of subjects: 0
Study 16007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing at T0 (immediate)
Number of subjects: 20
Study 16007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing at T1 (1 hour)
Number of subjects: 20
Study 16007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing at T4 (4 hours)
Number of subjects: 20
Study 16007473 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing at T24 (24 hours)
Number of subjects: 20
Study 12638326 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEI)
Number of subjects: 41
Study 10226901 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 68
Study 10226901 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin
Number of subjects: 68
Study 10226901 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 68
Study 10226901 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 68
Study 8669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 45
Study 8669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 45
Study 8669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electrical stimulation and biofeedback
Number of subjects: 45
Study 8669998 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 45
Study 1725911 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose verapamil treatment (Isoptin RR 240 mg twice daily)
Number of subjects: 196
Study 1725911 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of nifedipine four times daily
Number of subjects: 196
Study 1725911 — intervention group
Group type: COMPARATOR
Intervention: 90 mg of diltiazem three times daily
Number of subjects: 196
Study 7042502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimepropion-HCI
Number of subjects: 30
Study 7042502 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 29489608 — intervention group
Group type: EXPERIMENTAL
Intervention: Displayed checklist
Number of subjects: 131
Study 29489608 — intervention group
Group type: COMPARATOR
Intervention: Handheld checklist
Number of subjects: 131
Study 29489608 — intervention group
Group type: COMPARATOR
Intervention: No checklist
Number of subjects: 131
Study 26994212 — intervention group
Group type: EXPERIMENTAL
Intervention: M-quantile regression model
Number of subjects: 0
Study 26994212 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26422640 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle referral assessment
Number of subjects: 132
Study 26422640 — intervention group
Group type: COMPARATOR
Intervention: Usual assessment
Number of subjects: 132
Study 23897015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (phase change cooling vest)
Number of subjects: 10
Study 23897015 — intervention group
Group type: COMPARATOR
Intervention: Control (shorts and T-shirt)
Number of subjects: 10
Study 24075050 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 1080
Study 24075050 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 1080
Study 20693587 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg per kg of body weight)
Number of subjects: 9
Study 20693587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19041042 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiofrequency (CRF) thermocoagulation at 80 degrees C for 75 seconds
Number of subjects: 50
Study 19041042 — intervention group
Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF) at 42 degrees C with a pulse duration of 20 ms and pulse rate of two Hz for 120 seconds
Number of subjects: 50
Study 16172571 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET with a median SUVmax of 2.6 in cases with complete remission (CR)
Number of subjects: 40
Study 16172571 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET with a median SUVmax of 3.4 for tumors that did not relapse
Number of subjects: 40
Study 16172571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors with higher SUVmax
Number of subjects: 40
Study 14556918 — intervention group
Group type: EXPERIMENTAL
Intervention: Various chemotherapy regimens for advanced NSCLC
Number of subjects: 42661
Study 14556918 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger studies
Number of subjects: 42661
Study 14556918 — intervention group
Group type: EXPERIMENTAL
Intervention: More recent studies
Number of subjects: 42661
Study 14556918 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials from countries with only one published eligible study
Number of subjects: 42661
Study 14556918 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum and/or taxane and combination regimens
Number of subjects: 42661
Study 14556918 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status of patients
Number of subjects: 42661
Study 10589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (10 microg in 200 microL)
Number of subjects: 12
Study 10589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg in 200 microL)
Number of subjects: 12
Study 10589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1000 microg in 200 microL)
Number of subjects: 12
Study 10589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (100 microg in 200 microL)
Number of subjects: 12
Study 10589641 — intervention group
Group type: COMPARATOR
Intervention: Saline (200 microL)
Number of subjects: 12